Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill mandates Medicare, Medicaid, and CHIP coverage of defined cancer diagnostic and laboratory tests (including microarray, DNA/RNA sequencing, whole-exome and other next-generation sequencing) and their interpretation. It sets frequency limits (once at diagnosis, once at recurrence, and as needed for treatment planning/monitoring), prescribes Medicare payment rules (generally 80% of lesser of charge or analogous clinical lab amount, assignment-related at 100%), removes certain deductibles for these tests, and requires HHS to run an education program on genomic testing and encourage related medical education.
Supporters emphasize equitable access and reduced patient costs
Narrow, technical health proposal with bipartisan appeal likely to attract majority support in the House.
The bill mandates Medicare, Medicaid, and CHIP coverage of defined cancer diagnostic and laboratory tests (including microarray, DNA/RNA sequencing, whole-exome and other next-generation sequencing) and their interpretation.
It sets frequency limits (once at diagnosis, once at recurrence, and as needed for treatment planning/monitoring), prescribes Medicare payment rules (generally 80% of lesser of charge or analogous clinical lab amount, assignment-related at 100%), removes certain deductibles for these tests, and requires HHS to run an education program on genomic testing and encourage related medical education.
Medicaid and CHIP coverage becomes mandatory beginning January 1, 2027, with standard state-legislation timing exceptions.
Technically focused, non-ideological bill with fiscal impact; plausible bipartisan support but faces budgetary and procedural hurdles.
How solid the drafting looks.
Supporters emphasize equitable access and reduced patient costs
These are examples from the analysis, not a ranked list of the most-affected groups.
Supporters emphasize equitable access and reduced patient costs
Generally strongly supportive.
The bill expands access to genomic testing that can guide targeted cancer treatments and reduces patient cost barriers by modifying deductibles and requiring Medicaid/CHIP coverage.
The education provisions to train clinicians and inform the public are also consistent with improving equitable access.
Generally supportive but pragmatic and cautious.
The bill addresses a clear clinical need by standardizing coverage for genomic cancer testing, but it raises questions about federal costs, utilization controls, and administrative implementation at state level.
Skeptical.
While recognizing clinical value of genomic testing, this persona worries the bill expands federal mandates on states and increases Medicare/Medicaid spending without clear offsets or strict utilization controls.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically focused, non-ideological bill with fiscal impact; plausible bipartisan support but faces budgetary and procedural hurdles.
The bill has not accumulated any surfaced votes yet.
Supporters emphasize equitable access and reduced patient costs
Technically focused, non-ideological bill with fiscal impact; plausible bipartisan support but faces budgetary and procedural hurdles.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Finn Sawyer Access to Cancer Testing Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.